Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
04 Dezembro 2023 - 7:00AM
Business Wire
Mission-focused collaboration to explore
opportunities to help accelerate the discovery and development of
cancer drugs and diagnostics for patients
Cancer Research UK, one of the world’s largest charitable
funders of cancer research, its innovation unit, Cancer Research
Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading
precision oncology company, today announced a collaboration to
explore the sharing of technologies, data, and insights to advance
the development and precision of cancer detection and
treatment.
The agreement will enable the parties to discuss opportunities
for collaboration to support the charity’s research and clinical
development activities, focusing primarily on its clinical trials
run by its Centre for Drug Development. This includes the DETERMINE
trial – the first UK national precision medicine trial in rare
cancers, and other Cancer Research UK and Cancer Research Horizons
research collaborations.
Additional potential collaboration activities may include
sharing data and samples from the Cancer Research UK-funded
research network to further develop and validate Guardant’s
technologies, as well as explore other projects to accelerate the
discovery and development of cancer drugs and diagnostics.
“Partnering with Cancer Research UK grants us with a unique
opportunity to further validate Guardant’s unique technologies,
including our proprietary InfinityTM platform, while providing the
support needed for those with rare cancers and others who could
greatly benefit from precision oncology,” said Helmy Eltoukhy,
co-CEO of Guardant Health. “We’re looking forward to learning more
throughout this partnership to provide an even higher-level of
quality in our tools.”
Through this partnership, Guardant Health will further expand
its partnership with one of the world’s leading cancer charities,
Cancer Research UK, combining leading edge technology in
biotechnology with an expansive reach of more than 200 clinical
trials and studies in over a million people in the UK.
“Partnering with Guardant Health brings exciting potential for
us to accelerate our work by applying best-in-class data-driven
insights and technologies to our detection and treatment studies.
Our Centre for Drug Development has an excellent track record in
bringing novel therapeutics to first-in-human trials and we look
forward to seeing the positive impact this collaboration will have
on the Centre’s work and beyond,” said Tony Hickson, Chief Business
Officer for Cancer Research UK and Cancer Research Horizons.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360 CDx,
Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI®
tests for advanced stage cancer patients, and Guardant Reveal™ for
early-stage cancer patients. The Guardant Health screening
portfolio, including the ShieldTM test, aims to address the needs
of individuals eligible for cancer screening. For more information,
visit guardanthealth.com and follow the company on LinkedIn and
Twitter.
About Cancer Research UK
- Cancer Research UK is the world’s leading cancer charity
dedicated to saving lives through research, influence and
information.
- Cancer Research UK’s pioneering work into the prevention,
diagnosis and treatment of cancer has helped save millions of
lives.
- Cancer Research UK has been at the heart of the progress that
has already seen survival in the UK double in the last 50
years.
- Today, 2 in 4 people survive their cancer for at least 10
years. Cancer Research UK wants to accelerate progress and see 3 in
4 people surviving their cancer by 2034.
- Cancer Research UK supports research into the prevention and
treatment of cancer through the work of over 4,000 scientists,
doctors and nurses.
- Together with its partners and supporters Cancer Research UK is
working towards a world where people can live longer, better lives,
free from the fear of cancer.
For further information about Cancer Research UK's work or to
find out how to support the charity, please call 0300 123 1022 or
visit www.cancerresearchuk.org. Follow us on Twitter and
Facebook.
About Cancer Research Horizons
Cancer Research Horizons is the innovation engine of Cancer
Research UK – the world's largest charitable funder of cancer
research. We bring together world-leading minds, bold ideas and the
right partners to bridge the gap between academic research and
taking drugs to market. We focus on the tougher, more profound
ideas that can lead to true innovation, translating them into
effective treatments and diagnostics for cancer patients.
To date, we've played an instrumental role in forming over 60
spin-out companies. We've helped bring 11 cancer drugs to market,
borne out of Cancer Research UK's pioneering research. Through
these drugs, we have enabled in excess of 6 million courses of
treatment for cancer patients across the world.
With access to Cancer Research UK's network of 4,000 exceptional
researchers, and £300+ million of annual research spend, we're a
powerful partner in the fight to conquer cancer. By uniting our
commercial partnerships and therapeutic innovation capabilities,
Cancer Research Horizons is uniquely placed to support
translational funding, entrepreneurial development, licensing and
collaboration, spinout creation, and offer a full spectrum of drug
discovery and clinical capabilities.
Every penny we make goes back into funding the next bold steps,
to help bring forward the day when all cancers are conquered.
About Cancer Research UK’s Centre for Drug
Development
Cancer Research UK has an impressive record of developing novel
treatments for cancer. The Cancer Research UK Centre for Drug
Development has been pioneering the development of new cancer
treatments for 25 years, taking over 140 potential new anti-cancer
agents into clinical trials in patients. It currently has a
portfolio of 21 new anti-cancer agents in preclinical development,
Phase 1 or early Phase 2a clinical trials. Six of these new agents
have made it to market including temozolomide for brain cancer,
abiraterone for prostate cancer and rucaparib for ovarian cancer.
Two other drugs are in late development Phase 3 trials.
www.cruk.org.uk/cdd
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231204868972/en/
Melissa Marasco press@guardanthealth.com +1 650-647-3711
Eleanor Bennett Eleanor.Bennett@cancer.org.uk 020 3469 5370
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024